RÉSUMÉ
OBJECTIVE@#To explore the expression levels and clinical significance of helper T cell 1/helper T cell 2 (Th1/Th2) cytokine and interleukin-6 (IL-6) in patients with acute leukemia (AL) complicated by infection.@*METHODS@#68 patients with AL complicated by infection admitted to Wuhan Fifth Hospital from May 2017 to January 2020 were enrolled as study group, 50 AL patients without infection were enrolled as AL group, and 30 healthy volunteers checked in physical examination center were enrolled as healthy control group. The levels of serum tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-10 (IL-10), and peripheral blood Th1/Th2 cells subsets were measured and compared among the three groups. The serum IL-6, IL-10, TNF-α and Th1/Th2 were compared between the patients with mild to moderate infection (n=52) and septic shock (n=16). The relationship between IL-6, IL-10, TNF-α, Th1/Th2 and AL infection was analyzed.@*RESULTS@#The levels of IL-6, IL-10 , TNF-α, and the proportion of Th2 of the patients in study group and AL group were significantly higher than those in healthy control group (P<0.001), while the proportion of Th1 and Th1/Th2 were significantly lower than those in healthy control group (P<0.001). The levels of IL-6, IL-10 and TNF-α, and the proportion of Th2 the patients in study group were significantly higher than those in AL group (P<0.001), while the proportion of Th1 and Th1/Th2 were significantly lower than those in AL group (P<0.001). The serum IL-6, IL-10 and TNF-α level of the patients in septic shock group were significantly higher than those in mild-to-moderate infection group (P<0.001), while Th1/Th2 was lower than those in mild-to-moderate infection group (P<0.001). The results of ROC curve analysis showed that the area under the ROC curve (AUC) values of IL-6, IL-10, TNF-α and Th1/Th2 alone for the diagnosis of septic shock were 0.779, 0.761, 0.724 and 0.718, which were lower than that their combination (0.910) (P<0.05).@*CONCLUSION@#The levels of serum IL-6, IL-10 and TNF-α are high in patients with AL complicated infection and septic shock, while Th1/Th2 cell subsets is low. The combined detection of serum IL-6, IL-10, TNF-α and Th1/Th2 is a good diagnostic value for predicting the occurrence of severe septic shock.
Sujet(s)
Humains , Cytokines/métabolisme , Interleukine-10 , Interleukine-6/métabolisme , Leucémies/métabolisme , Choc septique/métabolisme , Lymphocytes auxiliaires Th1/métabolisme , Lymphocytes auxiliaires Th2/métabolisme , Facteur de nécrose tumorale alpha/métabolismeRÉSUMÉ
<p><b>OBJECTIVE</b>To explore the activation and proliferation of specific T cells induced by artificial antigen-presenting cells (aAPCs) simulated dendritic cells (DCs) and to observed the effect of these T cells on leukemic cell killing.</p><p><b>METHODS</b>aAPCs were developed by coating a human leukocyte antigen-immunoglobulin fusion protein ( HLA-lg), which was connected each one of the four CML28 antigen epitopes (DLMSSTKGL, DLMSSTKGL, ALFCGVACA, VLTFALDSV), and CD28-specific antibody, to magnet-beads CML cell specific peptides (CML28) served as target peptides. Bone marrow (BM) or peripheral blood (PB) mononuclear cells (MNCs) were isolated from HLA-A2 healthy volunteers, and co-cultured with aAPCs. Specific T lymphocyte were detected by flow cytometry. The fresh acute leukemic cells were used as target cells. The specific T cells incubated with leukemic cells for 4 h at ratios of 5:1, 10:1, 20:1, 40:1, 80: 1, respectively. The effect of leukemic cells killing was detected by lactate dehydrogenase release test.</p><p><b>RESULTS</b>The average ratio of CML-28 specific T lymphocyte in control group was (2.2 +/- 0.4)% and in experimental groups (DLMSSTKGL, DLMSSTKGL, ALFCGVACA, VLTFALDSV) were (13.5 +/- 1.6)%, (15.2 +/- 1.5)%, (14.7 +/- 1.8)% and (34.3 +/- 3.5)%, respectively, being significantly higher than that in control group (P < 0.01). Induction efficiencies of acute leukemic cells killing were significantly enhanced by increase of effector cells. The cytotoxic activity of specific T lymphocyte in one experimental group (VLTFALDSV) was much higher than that in other three experimental group (P < 0.05).</p><p><b>CONCLUSION</b>This "prime and expand" regimen should be an alternative method for large scale amplification of rare tumor-specific CTLs and aAPCs might be a useful tool for leukemia immunotherapy.</p>
Sujet(s)
Adolescent , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Cellules présentatrices d'antigène , Allergie et immunologie , Prolifération cellulaire , Cellules cultivées , Techniques de coculture , Cytotoxicité immunologique , Leucémies , Allergie et immunologie , Anatomopathologie , Activation des lymphocytes , Lymphocytes T , Biologie cellulaire , Allergie et immunologieRÉSUMÉ
This study was aimed to investigate the effect of artificial antigen-presenting cells (aAPCs) on inducing activation and proliferation of specific T-lymphocytes through stimulating biological function of dendritic cells with aAPCs in vitro. The specific antigen of chronic myeloid leukemia CML-28 was screened as objective antigen peptide by using magnetic microbeads as vector; the CML-28 epitope sequence (Vltfaldsv) was obtained by antigen epitope prediction software; this epitope was coupled with MHC molecule and used as first signal molecule, the B7-1 molecule was used as second signal molecule; these 2 molecules simultaneously were loaded onto surface of magnetic microbeads so as to contract aAPC complex. The bone marrow mononuclear cells were derived from HLA-A2(+) healthy bone marrow donors, CD8(+) T lymphocytes were screened and co-cultured with aAPC complex. During culture the 5, 6-carboxyfluorescein diacetate succinimidyl ester (CFSE) was added and proliferation of T-lymphocytes was detected by CPSE and proliferation level of specific T lymphocytes was detected by flow cytometry. The results showed that the proliferation level of CML-28 specific T lymphocytes obviously increased in experimental group, average level was 17.34 +/- 0.65%, while average level in control was 2.25 +/- 0.43%, there was significant difference between them (p < 0.01). It is concluded that the aAPC complex can mimic human APCs in vitro, and stimulate activation and proliferation of CD8(+) specific T lymphocytes.
Sujet(s)
Adolescent , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Présentation d'antigène , Allergie et immunologie , Cellules présentatrices d'antigène , Allergie et immunologie , Métabolisme , Antigènes néoplasiques , Allergie et immunologie , Biomimétique , Méthodes , Lymphocytes T CD8+ , Allergie et immunologie , Antigène HLA-A2 , Allergie et immunologie , Leucémie myéloïde chronique BCR-ABL positive , Allergie et immunologie , Activation des lymphocytes , Donneurs de tissusRÉSUMÉ
To investigate expression of plk-1 gene and PLK-1 protein in acute leukemia patients and its clinical significance, and to observe the distribution of PLk-1 protein in acute leukemin cells, the mononuclear cells were separated from the bone marrow or peripheral blood of acute leukemia patients, bone marrow benign proliferation individuals and normal individuals. The expression of plk-1 gene and PLK-1 protein in those cells were detected with RT-PCR and flow cytometry respectively, the distribution pattern of PLK-1 was observed by fluorescent inverted microscope. The result showed that the expressions of plk-1 gene and PLK-1 protein in mononuclear cells of acute leukemia patients were much higher than that of bone marrow benign proliferation individuals and normal individuals. Fluorescent inverted microscopy revealed that PLK-1 was highly concentrated in cytoplasm of acute leukemia cells during interphase of mitosis, and it was found that PLK-1 was mainly distributed between sister chromatid during the mitosis in mononuclear cells of acute leukemia patients, but the expressions of plk-1 gene and PLK-1 protein almost were not observed in cells of benign proliferative bone marrow and normal bone marrow. It is concluded that increased plk-1 gene and protein perhaps play an important role in abnormal proliferation of acute leukemia cells and correlate with the malignamcy of leukemia. plk-1 gene or PLK-1 protein may be considered as a new target of therapy, and one of useful indicators in evaluation of curative efficiency and prognosis.